Impact of Health Insurance Policy on Diabetes Management

  • Rebecca MyersonEmail author
  • Tianyi Lu
  • Anne Peters
  • Steven Fox
  • Elbert Huang


This chapter summarizes recent evidence on insurance policy as a tool to improve prevention, diagnosis, and treatment of diabetes. We note several key findings. First, recent availability of insurance coverage for diabetes prevention programs could have a significant impact on the diabetes epidemic, if coverage leads to adoption of these effective programs. Second, expansions in insurance coverage for low-income adults appear to accelerate diabetes diagnosis; in turn, diagnosis increases doctor visits for diabetes management. Third, expansions in insurance coverage and reduction of co-pays for essential diabetes medicines are associated with increased treatment of diabetes; these patterns have been found across studies of Medicare Part D, Medicaid, and private insurance and, if the effects persist, could improve diabetes outcomes. Finally, provider-side financial incentives to improve diabetes care for insured patients have not been shown to consistently improve diabetes management, but several large ongoing investigations may soon provide additional evidence. Together, the current evidence suggests that policies designed to improve access to and affordability of insurance coverage for diabetes prevention, screening, and treatment can play a key role in determining population-level diabetes management outcomes.


Diabetes management Access Insurance Public policy Medicaid Medicare Part D Value-based insurance coverage 


  1. Afendulis, C. C., He, Y., Zaslavsky, A. M., & Chernew, M. E. (2011). The impact of medicare part D on hospitalization rates. Health Services Research, 46(4), 1022–1038. Scholar
  2. Alva, M. L., Hoerger, T. J., Jeyaraman, R., Amico, P., & Rojas-Smith, L. (2017). Impact of the YMCA of the USA diabetes prevention program on Medicare spending and utilization. Health Affairs, 36(3), 417–424. Scholar
  3. American Diabetes Association. (2018). Economic costs of diabetes in the U.S. in 2017. Diabetes Care, dci180007.
  4. Association, A. D. (2018). 9. Cardiovascular disease and risk management: Standards of medical care in diabetes – 2018. Diabetes Care, 41(Supplement 1), S86–S104. Scholar
  5. Ayanian, J. Z., & Hamel, M. B. (2016). Transforming primary care – we get what we pay for. New England Journal of Medicine, 374(24), 2390–2392. Scholar
  6. Baicker, K., Taubman, S. L., Allen, H. L., Bernstein, M., Gruber, J. H., Newhouse, J. P., … Finkelstein, A. N. (2013). The Oregon experiment – effects of medicaid on clinical outcomes. New England Journal of Medicine, 368(18), 1713–1722. Scholar
  7. Baxter, M., Hudson, R., Mahon, J., Bartlett, C., Samyshkin, Y., Alexiou, D., & Hex, N. (2016). Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabetic Medicine: A Journal of the British Diabetic Association, 33(11), 1575–1581. Scholar
  8. Beran, D., & Yudkin, J. S. (2010). Looking beyond the issue of access to insulin: What is needed for proper diabetes care in resource poor settings. Diabetes Research and Clinical Practice, 88(3), 217–221. Scholar
  9. Bindman, A., Grumbach, K., Osmond, D., Komaromy, M., Vranizan, K., Lurie, N., … Stewart, A. (1995). Preventable hospitalizations and access to health care. JAMA, 274(4), 305–311.CrossRefGoogle Scholar
  10. Bowker, S. L., Mitchell, C. G., Majumdar, S. R., Toth, E. L., & Johnson, J. A. (2004). Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes. CMAJ, 171(1), 39–43. Scholar
  11. Bullard, K. M. (2018). Prevalence of diagnosed diabetes in adults by diabetes type – United States, 2016. MMWR. Morbidity and Mortality Weekly Report, 67. Scholar
  12. Burke, A., & Simmons, A. (2014). Increased coverage of preventive services with zero cost sharing under the Affordable Care Act (pp. 1–8). Department of Health and Human Services. Washington, D.C.Google Scholar
  13. Casalino, L. P. (2017). The medicare access and chip reauthorization act and the corporate transformation of American medicine. Health Affairs, 36(5), 865–869. Scholar
  14. CDC Diabetes Cost-effectiveness Group. (2002). Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA, 287(19), 2542–2551.CrossRefGoogle Scholar
  15. Centers for Medicare & Medicaid Services. (2018). Medicare advantage value-based insurance design model (VBID) fact sheet. Retrieved from
  16. Centers for Medicare and Medicaid Services. (2018). Medicare Diabetes Prevention Program (MDPP) Expanded Model. Retrieved May 29, 2018, from
  17. Chang, A., Liberman, J. N., Coulen, C., Berger, J. E., & Brennan, T. A. (2010). Value-based insurance design and antidiabetic medication adherence. American Journal of Pharmacy Benefits, 2(1), 39–44.Google Scholar
  18. Chernew, M. E., Shah, M. R., Wegh, A., Rosenberg, S. N., Juster, I. A., Rosen, A. B., … Fendrick, A. M. (2008). Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs (Project Hope), 27(1), 103–112. Scholar
  19. Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., & Peters, A. L. (2014). Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care, 37(7), 2034–2054. Scholar
  20. Choudhry, N. K., Fischer, M. A., Avorn, J., Schneeweiss, S., Solomon, D. H., Berman, C., … Shrank, W. H. (2010). At pitney bowes, value-based insurance design cut copayments and increased drug adherence. Health Affairs, 29(11), 1995–2001. Scholar
  21. Clemans-Cope, L., Kenney, G., Waidmann, T., Huntress, M., & Anderson, N. (2015). How well is CHIP addressing health care access and affordability for children? Academic Pediatrics, 15(3), S71–S77. Scholar
  22. Colagiuri, S., Cull, C. a., & Holman, R. R. (2002). Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care, 25(April), 1410–1417. Scholar
  23. Dale, S. B., Ghosh, A., Peikes, D. N., Day, T. J., Yoon, F. B., Taylor, E. F., … Brown, R. (2016). Two-year costs and quality in the comprehensive primary care initiative. New England Journal of Medicine, 374(24), 2345–2356. Scholar
  24. Davies, S. M., McDonald, K. M., Schmidt, E., Schultz, E., Geppert, J., & Romano, P. S. (2009). Expanding use of the AHRQ prevention quality indicators. Agency for Healthcare Research and Quality. Washington, D.C.Google Scholar
  25. DeLeire, T., Dague, L., Leininger, L., Voskuil, K., & Friedsam, D. (2013). Wisconsin experience indicates that expanding public insurance to low-income childless adults has health care impacts. Health Affairs, 32(6), 1037–1045. Scholar
  26. Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393–403. Scholar
  27. Diabetes Prevention Program Research Group. (2009). 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. The Lancet, 374(9702), 1677–1686. Scholar
  28. Diabetes Prevention Program Research Group. (2012). The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care, 35(4), 723–730. Scholar
  29. Finkelstein, A., Taubman, S., Wright, B., Bernstein, M., Gruber, J., Newhouse, J. P., … Baicker, K. (2012). The Oregon health insurance experiment: Evidence from the FIRST year. The Quarterly Journal of Economics, 127(3), 1057–1106.CrossRefGoogle Scholar
  30. Finkelstein, A. N., Taubman, S. L., Allen, H. L., Wright, B. J., & Baicker, K. (2016). Effect of medicaid coverage on ED use – further evidence from Oregon’s experiment. New England Journal of Medicine, 375(16), 1505–1507. Scholar
  31. Freedman, S., Nikpay, S., Carroll, A., & Simon, K. (2017). Changes in inpatient payer-mix and hospitalizations following Medicaid expansion: Evidence from all-capture hospital discharge data. PLoS One, 12(9), 1–9. Scholar
  32. Fung, V., Mangione, C. M., Huang, J., Turk, N., Quiter, E. S., Schmittdiel, J. A., & Hsu, J. (2010). Falling into the coverage gap: Part D drug costs and adherence for medicare advantage prescription drug plan beneficiaries with diabetes. Health Services Research, 45(2), 355–375. Scholar
  33. Ghosh, A., Simon, K., & Sommers, B. D. (2017). The effect of state medicaid expansions on prescription drug use: evidence from the affordable care act. NBER Working Paper Series, (23044).
  34. Gibson, T. B., Wang, S., Kelly, E., Brown, C., Turner, C., Frech-Tamas, F., … Mauceri, E. (2011). A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Affairs (Project Hope), 30(1), 109–117. Scholar
  35. Gilmer, T., O’Connor, P. J., Schiff, J. S., Taylor, G., Vazquez-Benitez, G., Garrett, J. E., … Desai, J. (2018). Cost-effectiveness of a community-based diabetes prevention program with participation incentives for Medicaid beneficiaries. Health Services Research. Scholar
  36. Goldman, D. P., Joyce, G. F., Escarce, J. J., Pace, J. E., Solomon, M. D., Laouri, M., … Teutsch, S. M. (2004). Pharmacy benefits and the use of drugs by the chronically ill. JAMA, 291(19), 2344–2350. Scholar
  37. Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007). Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA, 298(1), 61–69. Scholar
  38. Greene, J. A., & Riggs, K. R. (2015). Why is there no generic insulin? Historical origins of a modern problem. The New England Journal of Medicine, 372(12), 1171–1175. Scholar
  39. Herman, W. H. (2015). The cost-effectiveness of diabetes prevention: Results from the diabetes prevention program and the diabetes prevention program outcomes study. Clinical Diabetes and Endocrinology, 1, 9. Scholar
  40. Hirsch, I. B. (2016). Insulin in America: A right or a privilege? Diabetes Spectrum: A Publication of the American Diabetes Association, 29(3), 130–132. Scholar
  41. Hua, X., Carvalho, N., Tew, M., Huang, E. S., Herman, W. H., & Clarke, P. (2016). Expenditures and prices of antihyperglycemic medications in the United States: 2002–2013. JAMA, 315(13), 1400–1402. Scholar
  42. Huang, E. S., Basu, A., O’Grady, M., & Capretta, J. C. (2009). Projecting the future diabetes population size and related costs for the US. Diabetes Care, 32(12), 2225–2229. Scholar
  43. Jha, A. K., Aubert, R. E., Yao, J., Teagarden, J. R., & Epstein, R. S. (2012). Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Affairs, 31(8), 1836–1846. Scholar
  44. Katie K.. (2018, March 4). Reports find risk of non-ACA-compliant plans to be higher than federal estimates. Retrieved August 31, 2018, from
  45. Kaufman, H. W., Chen, Z., Fonseca, V. A., & McPhaul, M. J. (2015). Surge in newly identified diabetes among medicaid patients in 2014 within medicaid expansion states under the affordable care act. Diabetes Care, 38(5), 833–837. Scholar
  46. Keith, K. (2018, August 1). The short-term, limited-duration coverage final rule: The background, the content, and what could come next. Retrieved August 31, 2018, from
  47. Kolstad, J. T., & Kowalski, A. E. (2012). The impact of health care reform on hospital and preventive care: Evidence from Massachusetts. Journal of Public Economics, 96(11–12), 909–929. Scholar
  48. Levy, H., & Meltzer, D. (2008). The impact of health insurance on health. Annual Review of Public Health, 29, 399–409. Scholar
  49. Li, R., Zhang, P., Barker, L., & Hartsfield, D. (2010). Impact of state mandatory insurance coverage on the use of diabetes preventive care. BMC Health Services Research, 10(1), 133. Scholar
  50. Li, R., Zhang, P., & Narayan, K. M. V. (2008). Self-monitoring of blood glucose before and after Medicare expansion among Medicare beneficiaries with diabetes who do not use insulin. American Journal of Public Health, 98(2), 358–364. Scholar
  51. Liao, J. M., Shea, J. A., Weissman, A., & Navathe, A. S. (2018). Physician perspectives in year 1 of MACRA and its merit-based payment system: A National Survey. Health Affairs, 37(7), 1079–1086. Scholar
  52. Lipska, K. J., Ross, J. S., Wang, Y., Inzucchi, S. E., Minges, K., Karter, A. J., … Krumholz, H. M. (2014). National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Internal Medicine, 174(7), 1116–1124. Scholar
  53. McEwan, P., Bennett, H., Bolin, K., Evans, M., & Bergenheim, K. (2018). Assessing the economic value of maintained improvements in type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. Diabetic Medicine: A Journal of the British Diabetic Association, 35(5), 557–566. Scholar
  54. McWilliams, J. M., Chernew, M. E., & Landon, B. E. (2017). Medicare ACO program savings not tied to preventable hospitalizations or concentrated among high-risk patients. Health Affairs (Project Hope), 36(12), 2085–2093. Scholar
  55. McWilliams, J. M., Chernew, M. E., Landon, B. E., & Schwartz, A. L. (2015). Performance differences in year 1 of Pioneer accountable care organizations. New England Journal of Medicine, 372(20), 1927–1936. Scholar
  56. McWilliams, J. M., Hatfield, L. A., Chernew, M. E., Landon, B. E., & Schwartz, A. L. (2016). Early performance of accountable care organizations in medicare. New England Journal of Medicine, 374(24), 2357–2366. Scholar
  57. Mulcahy, A. W., Eibner, C., & Finegold, K. (2016). Gaining coverage through Medicaid or private insurance increased prescription use and lowered out-of-pocket spending. Health Affairs.,
  58. Myerson, R., & Laiteerapong, N. (2016). The affordable care act and diabetes diagnosis and care: Exploring the potential impacts. Current Diabetes Reports, 16(4), 27. Scholar
  59. Myerson, R., Lu, T., Tonnu-Mihara, I., & Huang, E. S. (2018). Medicaid eligibility expansions may address gaps in access to diabetes medications. Health Affairs, 37(8), 1200–1207. Scholar
  60. Myerson, R. M., Colantonio, L. D., Safford, M. M., & Huang, E. S. (2018). Does identification of previously undiagnosed conditions change care-seeking behavior? Health Services Research, 53(3), 1517–1538. Scholar
  61. National Center for Chronic Disease Prevention and Health Promotion. (2017). National Diabetes Statistics Report. Centers for Disease Control and Prevention.Google Scholar
  62. Nyweide, D. J., Lee, W., Cuerdon, T. T., Pham, H. H., Cox, M., Rajkumar, R., & Conway, P. H. (2015). Association of pioneer accountable care organizations vs traditional medicare fee for service with spending, utilization, and patient experience. JAMA, 313(21), 2152–2161. Scholar
  63. Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., … Howard, B. V. (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. Diabetes Care, 20(4), 537–544. Scholar
  64. Parekh, W., Streeton, S. E., Baker-Knight, J., Montagnoli, R., Nicoziani, P., & Marchesini, G. (2018). The economic burden of insulin-related hypoglycemia in adults with diabetes: An analysis from the perspective of the Italian healthcare system. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders, 9(3), 1037–1047. Scholar
  65. Peikes, D., Dale, S., Ghosh, A., Taylor, E. F., Swankoski, K., O’Malley, A. S., … Brown, R. S. (2018). The comprehensive primary care initiative: Effects on spending, quality, patients, and physicians. Health Affairs, 37(6), 890–899. Scholar
  66. Rewers, A., Dong, F., Slover, R. H., Klingensmith, G. J., & Rewers, M. (2015). Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. JAMA, 313(15), 1570–1572. Scholar
  67. Rogers, M. A. M., Lee, J. M., Tipirneni, R., Banerjee, T., & Kim, C. (2018). Interruptions in private health insurance and outcomes in adults with type 1 diabetes: A longitudinal study. Health Affairs (Project Hope), 37(7), 1024–1032. Scholar
  68. Sarafidis, P. A., Lazaridis, A. A., Ruiz-Hurtado, G., & Ruilope, L. M. (2017). Blood pressure reduction in diabetes: Lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews. Endocrinology, 13(6), 365–374. Scholar
  69. Schmittdiel, J., Ettner, S. L., Fung, V., Huang, J., Turk, N., Quiter, E., … Mangione, C. M. (2009). The Medicare part D coverage gap and diabetes beneficiaries. The American Journal of Managed Care, 15(3), 189–193.PubMedPubMedCentralGoogle Scholar
  70. Selph, S., Dana, T., Bougatsos, C., Blazina, I., Patel, H., & Chou, R. (2015). Screening for abnormal glucose and type 2 diabetes mellitus: A systematic review to update the 2008 U.S. preventive services task force recommendation. Rockville, MD: Agency for Healthcare Research and Quality (US). Retrieved from Scholar
  71. Selvin, E., & Ali, M. K. (2017). Declines in the incidence of diabetes in the U.S.-real progress or artifact? Diabetes Care, 40(9), 1139–1143. Scholar
  72. Silverstein, J., Klingensmith, G., Copeland, K., Plotnick, L., Kaufman, F., Laffel, L., … Clark, N. (2005). Care of Children and Adolescents with Type 1 diabetes: A statement of the American Diabetes Association. Diabetes Care, 28(1), 186–212. Scholar
  73. Soumerai, S. B., Mah, C., Zhang, F., et al. (2004). Effects of health maintenance organization coverage of self-monitoring devices on diabetes self-care and glycemic control. Archives of Internal Medicine, 164(6), 645–652. Scholar
  74. Squires, E., Duber, H., Campbell, M., Cao, J., Chapin, A., Horst, C., … Dieleman, J. L. (2018). Health care spending on diabetes in the U.S., 1996–2013. Diabetes Care, 41(7), 1423–1431. Scholar
  75. Taubman, S. L., Allen, H. L., Wright, B. J., Baicker, K., & Finkelstein, A. N. (2014). Medicaid increases emergency-department use: Evidence from Oregon’s health insurance experiment. Science (New York, N.Y.), 343(6168), 263–268. Scholar
  76. Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., … Finnish Diabetes Prevention Study Group. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine, 344(18), 1343–1350. Scholar
  77. Turner, R., Holman, R. R., Stratton, I. M., Cull, C. A., Frighi, V., Manley, S. E., … Wright, D. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 217, 703–713. Scholar
  78. UK Prospective Diabetes Study group. (1998a). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (London, England), 352(9131), 854–865.CrossRefGoogle Scholar
  79. UK Prospective Diabetes Study group. (1998b). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837–853. Scholar
  80. Wilper, A. P., Woolhandler, S., Lasser, K. E., McCormick, D., Bor, D. H., & Himmelstein, D. U. (2009). Hypertension, diabetes, and elevated cholesterol among insured and uninsured U.S. adults. Health Affairs (Project Hope), 28(6), 1151–1159. Scholar
  81. Wynne, B. (2016). For medicares new approach to physician payment, big questions remain. Health Affairs, 35(9), 1643–1646. Scholar
  82. Zhang, Y., Donohue, J. M., Lave, J. R., O’Donnell, G., & Newhouse, J. P. (2009). The effect of medicare part D on drug and medical spending. New England Journal of Medicine, 361(1), 52–61. Scholar
  83. Zickafoose, J. S., Smith, K. V., & Dye, C. (2015). Children with special health care needs in CHIP: Access, use, and child and family outcomes. Academic Pediatrics, 15(3), S85–S92. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Rebecca Myerson
    • 1
    Email author
  • Tianyi Lu
    • 2
  • Anne Peters
    • 3
  • Steven Fox
    • 2
  • Elbert Huang
    • 4
  1. 1.Department of Population Health SciencesUniversity of Wisconsin MadisonMadisonUSA
  2. 2.Department of Pharmaceutical and Health EconomicsUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Department of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  4. 4.Department of MedicineUniversity of ChicagoChicagoUSA

Personalised recommendations